Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 365

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 365
---
 combination period. However, if the Initial Stockholders should acquire Public Shares in or after the IPO, they will
be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a
business combination within the business combination period. The underwriter has agreed to waive its rights to the deferred underwriting
commission (see Note 6) held in the Trust Account in the event the Company does not complete a business combination within the business
combination period, and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available
to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual
assets remaining available for distribution (including Trust Account assets) will be only $10.20 per share held in the Trust Account.
In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any
claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has
discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with
respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held
in the Trust Account or to any claims under the Company’s indemnity of the underwriter of the IPO against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an
executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability
for such third-party claims.

The Company will seek to reduce the possibility
that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers
(except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which
the Company does business, execute agreements waiving any right, title, interest or claim of any kind in or to monies held in the Trust
Account.

Business Combination Agreement with CERo Therapeutics, Inc. (“CERo”)

On June 4, 2023, the Company entered into
a business combination agreement and plan of reorganization (the “Business Combination